MedTrace Logo

Sodium-Glucose Cotransporter 2 Inhibitor Use in a National Heart Failure Telemonitoring Program

NCT07022379 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13660

Last updated 2026-03-25

No results posted yet for this study

Summary

This observational cohort study evaluates temporal trends and determinants of sodium-glucose cotransporter 2 inhibitor (SGLT2i) prescriptions among adults with chronic heart failure enrolled in a nationwide remote monitoring program in France between 2021 and 2024. The analysis examines SGLT2i use at the time of enrollment in relation to left ventricular ejection fraction subgroups and evolving scientific evidence, including major clinical trial publications and guideline updates. Demographic, clinical, and healthcare setting factors associated with SGLT2i prescription in routine clinical practice are assessed using retrospective data from the remote monitoring program database. No study-mandated interventions were performed, and all treatments were prescribed as part of usual care.

Conditions

  • Heart Failure
  • Heart Failure With Preserved Ejection Fraction (HFPEF)
  • Heart Failure With Reduced Ejection Fraction
  • Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

Interventions

OTHER

SGLT2 Inhibitor Use

Prescription of a sodium-glucose cotransporter 2 inhibitor as part of routine clinical care at the time of enrollment in the remote monitoring program. Treatment decisions were made by the treating physician and were not study-mandated.

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    collaborator OTHER

  • Satelia

    lead INDUSTRY

Principal Investigators

  • Nicolas Girerd, PhD, MD · CHRU Nancy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07022379 on ClinicalTrials.gov